US Plows $354m Into Phlow
Start-Up Is Awarded Contract To Manufacture Essential Medicines In US
US start-up Phlow has been awarded federal government funding of $354m as part of a contract to manufacture essential medicines in the US amid the COVID-19 pandemic, in partnership with AMPAC Fine Chemicals and Civica Rx.
You may also be interested in...
Civica Rx’s chief operating officer Ned McCoy is to step up as CEO, ahead of the company’s landmark manufacturing facility commencing operations in early 2024.
Phlow partners to provide continuous manufacturing research and development services for active pharmaceutical ingredients and registered starting materials. The company has also announced the appointment of Malcolm Berry as a senior consultant at the company’s R&D team.
US-based Phlow and Fresenius Kabi have announced an alliance to supply essential medicines, including injectables, for public health emergencies and to Children’s Hospital Coalition, a project by Phlow. In an exclusive interview with Generics Bulletin, Phlow chief business officer Dan Hackman talks about the partnership, addressing US supply chain disruptions, domestic manufacturing and more.